The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
58th ERA-EDTA Congress - Fully Virtual 2021 Industry Sponsored by Bayer June 5-8, 2021
Video of the Bayer Industry Symposium at the ERA-EDTA
Thank you for your interest! Watch below the session recording of the Bayer Industry Symposia at ERA-EDTA Fully Virtual Congress 2021.
Access to the video will be available after the virtual congress presentation.
Finerenone
Sunday 6 June, 2021 | 13:30 - 14:30 CEST
Nonsteroidal MRAs to improve outcomes in patients with CKD and T2D
María José Soler (Chair), Katherine Tuttle, Rajiv Agarwal, and Pantelis Sarafidis discuss the role of inflammation and fibrosis as independent drivers of CKD in T2D progression, and the link between MR overactivation and inflammation and fibrosis. Clinical data from the FIDELIO-DKD trial, suggesting finerenone (a novel, selective, nonsteroidal MRA) may be an effective treatment for kidney and CV protection in patients with CKD and T2D is presented, and insights into which patients may be suitable for finerenone treatment, based on these data, are shared. Also included a complete faculty 10-minute question & answer session Chaired by María José Soler with live questions from the ERA-EDTA delegation.
Presentation: TBC
View Video
ERA-EDTA: References and further reading
ERA-EDTA: References and further reading
Overview of the latest clinical trials
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date last accessed: 7 May 2021
ERA-EDTA: References and further reading
SGLT-2is in CKD
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date last accessed: 7 May 2021
ERA-EDTA: References and further reading
GLP-1RAs in CKD and T2D
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date last accessed: 7 May 2021
ERA-EDTA: References and further reading
Effects of SGLT-2is on kidney and CV outcomes in CKD
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date last accessed: 7 May 2021
ERA-EDTA: References and further reading
The relationship between the MR and CKD in T2D
Click on the link to access individual sessions at the congresses. Please note, you may have to be logged in to the congress site in some instances for direct access to the content.
Date last accessed: 7 May 2021
